Stay updated with breaking news from Bodor Laboratories. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brickell Biotech (NASDAQ:BBI – Get Rating) and bluebird bio (NASDAQ:BLUE – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Analyst Recommendations This is a breakdown of recent recommendations […]
Brickell Biotech (NASDAQ:BBI – Get Rating) and Vaxcyte (NASDAQ:PCVX – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk. Insider and Institutional Ownership 71.5% of Vaxcyte shares are owned by […]
Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints - read this article along with other careers information, tips and advice on BioSpace
BOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on...
Published: Apr 27, 2021 - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021 BOULDER, Colo., April 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced completion of patient enrollment in the Phase 3 pivotal Cardigan I study and that the Cardigan II study has surpassed 50% enrollment. Both studies are eval...